Metraipolis › archive › dc_af2912b95176

FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG) — Europe PMC PMID:40940827

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40940827
DOI
10.3390/cancers17172730
License (as archived)
solo-consultazione
Archived
2026-11-10T10:27:18.111Z
SHA-256 of the archived text
91e8572b94885d4ef69c2c60e2dad7f2e45e5762035d36607df58e479c8ff950
Stable URL of this page
https://metraipolis.com/documento/dc_af2912b95176

How to cite

FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG) — Europe PMC PMID:40940827 — Europe PMC (en), https://europepmc.org/article/MED/40940827 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_af2912b95176 (Metraipolis archive dc_af2912b95176, sha256 91e8572b94885d4ef69c2c60e2dad7f2e45e5762035d36607df58e479c8ff950)
BibTeX
@misc{dcaf2912b95176,
  title = {FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG) — Europe PMC PMID:40940827},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40940827},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_af2912b95176; sha256 91e8572b94885d4ef69c2c60e2dad7f2e45e5762035d36607df58e479c8ff950},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40940827. Agents can read the archived copy with the MCP tool read_document.